Red Bull vs. F1 Engine Noise: Legal Confident Claim
- Red Bull is certain the compression ratio of its 2026 Formula 1 engine is within the regulations, as Red Bull Powertrains director Ben Hodgkinson says the recent controversy...
- With Red Bull's season launch in Detroit, the partnership between Red Bull Powertrains and Ford is officially being kicked off, even though in practice work on the engine...
- The question remains how competitive a newcomer can be from the start - especially given the increased share of electrical power and the relative inexperience of both Red...
Red Bull is certain the compression ratio of its 2026 Formula 1 engine is within the regulations, as Red Bull Powertrains director Ben Hodgkinson says the recent controversy is “a lot of noise about nothing”.
With Red Bull’s season launch in Detroit, the partnership between Red Bull Powertrains and Ford is officially being kicked off, even though in practice work on the engine project has already been going for four years at the red Bull Campus in Milton Keynes.
The question remains how competitive a newcomer can be from the start – especially given the increased share of electrical power and the relative inexperience of both Red Bull and Ford in this area, at least in Formula 1.
In the build-up to winter testing in Barcelona, however, most of the attention has focused on the internal combustion engine, and more specifically on the compression ratio. It’s the ratio between the largest and smallest volume in the cylinder. Under the previous set of regulations that ratio was still 18:1, but for 2026 it has been reduced to 16:1 – among other reasons to make the rules more accessible for newcomers.
Other manufacturers have become aware that Mercedes and Red Bull Powertrains would comply with the 16:1 limit during static tests at ambient temperature – which, as it stands, is the only way the FIA checks it – but that they could achieve a higher ratio while running at higher temperatures.
Audi, Ferrari and Honda have collectively raised the issue with the FIA, after which it has been placed on the agenda for a meeting with technical experts on 22 January – which covers multiple topics, including the aero side of the new ruleset.
Table of Contents
The Inflation Reduction Act (IRA) of 2022 allows Medicare to negotiate prices for certain high-cost prescription drugs, aiming to lower healthcare costs for seniors and taxpayers. This marks a significant shift in U.S. pharmaceutical policy,as previous law prohibited Medicare from directly negotiating drug prices.
How Medicare drug Price Negotiation Works
Direct negotiation under the IRA focuses on a limited number of drugs initially,expanding over time. The Centers for medicare & Medicaid Services (CMS) selects drugs lacking generic or biosimilar competition, with the highest total costs to Medicare. Negotiations occur between CMS and the drug manufacturers, with prices taking effect in phases starting in 2026.
The first 10 drugs selected for negotiation were announced in September 2023, and include medications treating conditions like diabetes, heart failure, and blood clots. These drugs accounted for $50.5 billion in Medicare Part D and Part B gross drug costs in 2022,according to CMS data.
Impact on Pharmaceutical Companies
The IRA’s drug pricing provisions have drawn strong opposition from the pharmaceutical industry, notably PhRMA (Pharmaceutical Research and Manufacturers of America), the industry’s lobbying group. Companies argue that price negotiation will stifle innovation by reducing revenue available for research and development.
Such as, Merck & Co.,in its 2023 annual report,cited the IRA as a potential risk factor,stating it “could considerably reduce our revenues and profitability.” However, supporters of the IRA contend that the law strikes a balance between affordability and innovation, allowing companies to still profit while ensuring access to lower-cost medications for Medicare beneficiaries.
Legal Challenges and Court Rulings
Several lawsuits were filed challenging the constitutionality of the IRA’s drug price negotiation provisions. The Supreme Court heard oral arguments in March 2024 in NetChoice LLC and the Chamber of Commerce of the United States of America v. Xavier Becerra, Secretary of Health and Human Services, concerning the legality of the negotiation process.
On June 21, 2024, the Supreme Court ruled unanimously in favor of the Biden governance, upholding the constitutionality of the drug price negotiation provisions. The court found that the plaintiffs lacked standing to bring the case, as they had not demonstrated a concrete injury caused by the law.
Future Implications and Expansion of Negotiations
The IRA’s impact will expand over time. The law initially allows for negotiation of 10 drugs in 2026, increasing to 15 drugs in 2027, and 20 drugs by 2029. Furthermore, the Inflation Reduction Act also includes provisions to cap out-of-pocket prescription drug costs for Medicare beneficiaries at $2,000 per year, beginning in 2025.
The Kaiser Family Foundation (KFF) estimates that the IRA could save Medicare beneficiaries billions of dollars over the next decade, while also reducing federal spending on prescription drugs. The Congressional Budget Office (CBO) initially estimated the IRA would reduce the federal deficit by $264 billion over ten years, with a significant portion of those savings coming from lower drug costs.